

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

HOLDING ANNOUNCEMENT

Reference is made to the announcement of Tongfang Kontafarma Holdings Limited (the “**Company**”) dated 29 November 2016 in relation to, among others, trading halt in the shares of the Company (the “**Shares**”) and a potential subscription of shares in a target company which constitutes very substantial acquisition for the Company (the “**Transaction**”).

The Company makes this holding announcement to inform its shareholders of the current status of the Transaction. On 29 November 2016 (before trading hours), the Company entered into a share subscription agreement (the “**Share Subscription Agreement**”) with Binex Co., Ltd. (the “**Target Company**”), a company listed on Korean Securities Dealers Automated Quotations of Korea Exchange. Pursuant to the Share Subscription Agreement, the Company has conditionally agreed to subscribe from the Target Company, and Target Company has conditionally agreed to issue to the Company (or its wholly owned subsidiary designated by it), 13,182,298 shares of common stock of the Target Company (the “**Subscription Shares**”), representing approximately 29% of the total issued share capital of the Target Company as enlarged by the Subscription Shares (the “**Subscription**”). The Target Company is principally engaged in the manufacturing and selling of pharmaceuticals mainly in Korea.

As one of the applicable percentage ratios in respect of the Subscription exceeds 100%, the Subscription constitutes a very substantial acquisition for the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Trading in the Shares has been suspended with effect from 9:00 a.m. on 29 November 2016, pending the release of an announcement relating to the Transaction (the “**Announcement**”). The Company is currently in the process of finalising the Announcement and will, subject to obtaining the clearance from the Stock Exchange, publish the Announcement as soon as possible and resume trading in the Shares.

Suspension of trading in the Shares will continue until the publication of the Announcement.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 15 December 2016

As at the date of this announcement, the Board comprises three executive directors, namely Mr. Huang Yu (Chairman), Mr. Ng Qing Hai (Managing Director) and Mr. Zhang Yi and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.